Repligen gains on new strategic focus

Repligen Corp. (NASDAQ:RGEN) gained $0.62 (16%) to $4.54 on Thursday after the company said it will now seek to partner its therapeutic product pipeline to focus resources on expanding its bioprocessing business, which recorded 2Q12 revenue of $11.7 million, up from $4.4 million in the prior year's period. The company's pipeline includes pancreatic imaging agent SecreFLo ( RG1068), for which FDA issued a complete response letter in June asking for an additional clinical trial, as well as two products in Phase I testing: RG2833 for Friedreich's ataxia; and RG3039 for spinal muscular atrophy (SMA) (see BioCentury Extra, June 22). ...